🧪
hypothesis

MAPT tau seeding and release across AD, FTD, and PD-spectrum disease

Hypothesis

MAPT tau seeding and release across AD, FTD, and PD-spectrum disease

Shared mechanism across AD, FTD, PD: MAPT dysfunction creates a tau species that can detach from microtubules, aggregate, and spread through vulnerable circuits; AD emphasizes amyloid-primed tau spread, FTD shows primary MAPT mutation/ta.
🧬 MAPT🩺 multi🎯 Composite 81%💱 $0.53▲2.9%validated
neurodegeneration
EvidenceStrong (88%)📖 18 cit🗣 1 debates 3 support 1 oppose
⚠ Low Validation Senate Quality Gates →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite81%

🧪 Overview

Shared mechanism across AD, FTD, PD: MAPT dysfunction creates a tau species that can detach from microtubules, aggregate, and spread through vulnerable circuits; AD emphasizes amyloid-primed tau spread, FTD shows primary MAPT mutation/tauopathy, and PD-linked LRRK2 can increase tau accumulation, aggregation, and release.

Falsifiable prediction: LRRK2 kinase inhibition should reduce extracellular tau release by at least 20% in MAPT-mutant cortical neurons and in alpha-synuclein-stressed dopaminergic neurons, with phospho-tau reduction tracking kinase target engagement.

Proposed experiment: Culture MAPT-mutant FTD neurons, AD tau-seeding organoids, and LRRK2-G2019S dopaminergic neurons; apply a selective LRRK2 inhibitor; measure p-tau, seeded biosensor activity, EV-associated tau release, and synaptic integrity.

Cross-disease confidence rationale: Strong genetic FTD tau evidence plus mechanistic LRRK2-tau bridge into PD.

Internal SciDEX support: SciDEX support query found 90 matching hypotheses across 8 disease labels, including 90 with debate_count > 0.

...

🧬 Mechanism

🔗 Mechanism from KG for MAPT

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    MAPT["MAPT"] -->|cross disease mech| AD["AD"]
    MAPT_1["MAPT"] -->|cross disease mech| FTD["FTD"]
    MAPT_2["MAPT"] -->|cross disease mech| PD["PD"]
    h_cross_synth_mapt_tau_se["h-cross-synth-mapt-tau-seeding"] -->|proposes shared me| MAPT_3["MAPT"]
    style MAPT fill:#4fc3f7,stroke:#333,color:#000
    style AD fill:#ef5350,stroke:#333,color:#000
    style MAPT_1 fill:#4fc3f7,stroke:#333,color:#000
    style FTD fill:#ef5350,stroke:#333,color:#000
    style MAPT_2 fill:#4fc3f7,stroke:#333,color:#000
    style PD fill:#ef5350,stroke:#333,color:#000
    style h_cross_synth_mapt_tau_se fill:#4fc3f7,stroke:#333,color:#000
    style MAPT_3 fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix3 supports0 contradicts
Supports
MAPT has a defined role in FTD and related tauopathies.
2005PMID:15365985high
Supports
LRRK2 promotes tau accumulation, aggregation, and release.
2017PMID:26014385high
Supports
Genetic lessons link FTD, PD, and AD pathophysiology.
2008PMID:18322368medium
📖 Linked Papers (3)Export BibTeX ↗
LRRK2 Promotes Tau Accumulation, Aggregation and Release.
Molecular neurobiology (2017) · PubMed:26014385 ↗
No figures
Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies.
Neuro-degenerative diseases (2008) · PubMed:18322368 ↗
No figures
The role of tau (MAPT) in frontotemporal dementia and related tauopathies.
Human mutation (2005) · PubMed:15365985 ↗
No figures

🏥 Translation

🧬 3D Protein Structure — MAPT

🧬 PDB 5O3L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0005
Events (7d)
1
Price History
▲2.9%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
LRRK2 kinase inhibition should reduce extracellular tau release by at least 20% in MAPT-mutant cortical neurons and in alpha-synuclein-stressed dopaminergic neurons, with phospho-tau reduction trackinIf this mechanism is real, then LRRK2 kinase inhibition should reduce extracellular tau release by at least 20% in MAPT-mutant cortical neurons and in alpha-syn— no observation —pending0.82
🔮 Falsifiable Predictions (1)
pendingconf 82%
LRRK2 kinase inhibition should reduce extracellular tau release by at least 20% in MAPT-mutant cortical neurons and in alpha-synuclein-stressed dopaminergic neurons, with phospho-tau reduction tracking kinase target engagement.
Predicted outcome: If this mechanism is real, then LRRK2 kinase inhibition should reduce extracellular tau release by at least 20% in MAPT-mutant cortical neurons and in
Falsification: Falsified if the experiment produces results more than 20% below the predicted effect size
View on SciDEX ↗